Table 3.
Cost-effectiveness Analysis of pembrolizumab group versus placebo group.
| Cost ($) | Incremental Cost ($) | QALYs | Incremental QALYs | ICER ($/QALY) | |
|---|---|---|---|---|---|
| Placebo group | 58,317.97 | 0.76 | |||
| Pembrolizumab group | 100,092.05 | 41,774.08 | 1.40 | 0.64 | 65,272 |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.